Cargando…
CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
BACKGROUND: Epidermal growth factor receptor (EGFR) mutations, such as exon 19 deletion and exon 21 L858R, are driver oncogenes of non-small cell lung cancer (NSCLC), with EGFR tyrosine kinase inhibitors (TKIs) being effective against EGFR-mutant NSCLC. However, the efficacy of EGFR-TKIs is transien...
Autores principales: | Hara, Naofumi, Ichihara, Eiki, Kano, Hirohisa, Ando, Chihiro, Morita, Ayako, Nishi, Tatsuya, Okawa, Sachi, Nakasuka, Takamasa, Hirabae, Atsuko, Abe, Masaya, Asada, Noboru, Ninomiya, Kiichiro, Makimoto, Go, Fujii, Masanori, Kubo, Toshio, Ohashi, Kadoaki, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654429/ https://www.ncbi.nlm.nih.gov/pubmed/38025818 http://dx.doi.org/10.21037/tlcr-23-99 |
Ejemplares similares
-
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers
por: Watanabe, Hiromi, et al.
Publicado: (2021) -
Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression
por: Nishii, Kazuya, et al.
Publicado: (2021) -
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
por: Ninomiya, Kiichiro, et al.
Publicado: (2018) -
Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer
por: Ichihara, Eiki, et al.
Publicado: (2018) -
Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease
por: Okawa, Sachi, et al.
Publicado: (2021)